Press releases

20 April, 2020

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Wednesday, 20 May 2020 at Medicon V ...

3 April, 202019 February, 2024

Regulatory

NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...

17 March, 2020

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...

19 February, 2020

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2019

Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...

19 February, 2020

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 3 pm on Tuesday 17 March 2020 at Medicon Village, Scheelevägen 2, ...

19 February, 2020

Regulatory

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333

Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has reso ...

16 December, 2019

Regulatory

NeuroVive announces settlement in dispute with CicloMulsion AG

Lund, Sweden, 16 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certa ...

20 November, 2019

Regulatory

NeuroVive Pharmaceutical AB Interim Report January – September 2019

Continued progress in KL1333.

21 August, 2019

Regulatory

NeuroVive Pharmaceutical AB Interim Report January – June 2019

Focus on genetic mitochondrial diseases

27 July, 2019

Regulatory

NeuroVive’s NeuroSTAT project receives FDA Fast Track designation

Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company’s candidate drug NeuroSTAT, in development for treatment of moderate to s ...

4 July, 2019

Regulatory

NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study

Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...

21 May, 2019

Regulatory

NeuroVive Pharmaceutical AB Interim Report January – March 2019

First subjects enrolled in the KL1333 study